Advisor Group’s Amicus Therapeutics FOLD Stock Holding History

Advisor Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$12K	Buy	1,307 +14	+1%	+$128	﹤0.01%	4242
2019 Q3	$11K	Sell	1,293 -134	-9%	-$1.45K	﹤0.01%	4285
2019 Q2	$18K	Buy	1,427 +956	+203%	+$12.1K	﹤0.01%	4031
2019 Q1	$7K	Buy	471 +46	+11%	+$562	﹤0.01%	4518
2018 Q4	$4K	Sell	425 -506	-54%	-$5.56K	﹤0.01%	4604
2018 Q3	$11K	Sell	931 -2,000	-68%	-$28K	﹤0.01%	4233
2018 Q2	$46K	Sell	2,931 -5	-0.2%	-$76	﹤0.01%	3155
2018 Q1	$44K	Buy	2,936 +2,495	+566%	+$38K	﹤0.01%	3158
2017 Q4	$7K	Hold	441	–	–	﹤0.01%	4269
2017 Q3	$7K	Buy	441 +328	+290%	+$4.34K	﹤0.01%	4129
2017 Q2	$1K	Hold	113	–	–	﹤0.01%	4623
2017 Q1	$1K	Hold	113	–	–	﹤0.01%	4519
2016 Q4	$1K	Hold	113	–	–	﹤0.01%	4350
2016 Q3	$1K	Buy	+113	New	+$763	﹤0.01%	4292

Other funds holding FOLD

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Advisor Group's FOLD Position: Q4 2019 in Review

Advisor Group increased its Amicus Therapeutics (FOLD) stake by 1.1% in Q4 2019, buying an estimated $128 and bringing the position to 1,307 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #4242.

Advisor Group first reported a position in FOLD in Q3 2016 and has held it in 14 quarters since. The position peaked at $46K in Q2 2018. 224 funds tracked by Wall St. Rank hold FOLD as of Q4 2019.

Advisor Group held 1,307 shares of Amicus Therapeutics worth $12K as of Q4 2019.
Advisor Group bought 14 Amicus Therapeutics shares in Q4 2019, an estimated $128.
Amicus Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4242 holding.
Advisor Group first reported a position in Amicus Therapeutics in Q3 2016 and has held it in 14 quarters since.
Advisor Group's Amicus Therapeutics position peaked at $46K in Q2 2018.
224 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.